A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).~Primary Objective: To determine whether dronabinol will improve pain and QOL in adults with SCD and chronic pain.~Secondary Objectives: To assess dronabinol's effect on markers of inflammation in patients with SCD compared to placebo.~To determine the safety and tolerability of dronabinol use in adults with SCD compared to placebo.
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).